Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly introduced hypoglycemic drugs that work by inhibiting glucose reabsorption at proximal renal tubules. The use of SGLT2 inhibitors in nontransplant diabetic patients with or without cardiovascular disease has well-established efficacy and safety. The risks of renal graft dysfunction and urinary tract infections might be the limiting factors for their use in renal transplant patients. Data regarding the safety and long-term efficacy of SGLT2 inhibitors use in diabetic renal transplant patients is scanty. The aim of the study is to report our experience with use of SGLT2 inhibitors in 8 diabetic renal transplant patients supported by literature review. Eight diabetic renal transplant patients were recruited from Tawam hospital during the period between June 2016 and January 2019. Demographic, clinical, and laboratory data were collected and analyzed. Adding SGLT2 resulted in significant decrease in hemoglobin A1c and body mass index after 12 months of treatment. There was significant negative correlation between the duration of treatment with SGLT2 and hemoglobin A1c. Diabetic renal transplant patients with stable kidney function had better glycemic control with use of SGLT2 inhibitors. There was no deterioration of kidney function and risk of recurrent urinary tract infection was low.

Maternal and cord blood prolactin level and pregnancy complications.

OBJECTIVES: To explore the correlation between maternal and cord blood prolactin, the correlation between cord prolactin and birth weight, and to compare cord blood prolactin in new-borns of women with normal pregnancy and women with pregnancy complications namely; gestational hypertension, gestational diabetes and preterm labour. METHODS: This study was performed from September to December 2018. Thirty-two women, delivered at Baghdad teaching hospital, and their newborns (32) were included. Maternal blood (5 ml) was taken before labour and cord blood (5 ml) was collected after placenta expulsion. Maternal and cord blood prolactin were analysed using fluorescence immunoassay. RESULTS: Cord blood prolactin was higher in babies born to hypertensive women (405.28±77.52 ng/ml) than normal pregnancy women (244.80±60.80 ng/ml), P=0.000. Also, cord prolactin in gestational hypertension group was significantly higher than diabetic (P=0.006) and preterm labour (P=0.000) groups. No significant difference was noticed in cord blood prolactin in newborns of diabetic and normal pregnancy women (299.28±37.01, 244.80±60.80 ng/ml respectively, P=0.053). Preterm babies had lower cord prolactin (204.57±22.90 ng/ml) than normal pregnancy babies (244.80±60.80 ng/ml), however the difference was non-significant, P=0.118. Positive correlation was found between cord and maternal prolactin (P=0.000) and between cord prolactin and birth weight (P=0.018). CONCLUSION: Cord blood prolactin is high in newborns of hypertensive women, low in preterm neonates. Diabetes has no effect on cord prolactin level.